Low dose 2-Cda schedule activity in Splenic Marginal Zone Lymphomas

Hematological Oncology

Volumn 21, Issue 4, 2003, Pages 163-168

  Riccioni, R ^a   Caracciolo, F ^a   Galimberti, S ^a   Cecconi, N ^a   Petrini, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

2 CdA therapy; Indolent lymphoma; Splenic marginal zone lymphoma

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CLADRIBINE; COTRIMOXAZOLE;

ADULT; AGED; ALOPECIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; LOW DRUG DOSE; LYMPHOMA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

2-CHLOROADENOSINE; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYADENOSINES; FEMALE; HUMANS; LYMPHOMA; MIDDLE AGED; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0742288275     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.717     Document Type: Review

References (22)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
2. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma: an update on recent advances. Histopathology 2002; 40: 117-126.
3. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organisation classification of neoplastic diseases of the hematopoietic and lymphoid tissues: a progres report. Am J Clin Pathol 1999; 111: 8-12.
4. Isaacson PG. Splenic marginal zone lymphoma. In Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). IARC: Lyon, 2001; 135-137.
5. Maryniak RK, Prochorec-Sobieszek M. Primary splenic B-cell lymphoma (marginal zone lymphoma). Clinicopathological evaluation of 10 cases. Pol J Pathol 2000; 51: 185-190.
6. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymph 2002; 3: 41-47.
7. Chacòn JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
8. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
9. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996; 93: 731-736.
10. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991; 78: 206-209.
11. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-1121.
12. Cheson BD. New antimetabolites in the treatment of human malignancies. Semin Oncol 1992; 19: 695-706.
13. Galimberti S, Marasca R, Caracciolo F, et al. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 581-587.
14. El Weshi A, Ribrag V, Girinski T, El Hajj M, Dhermain F, Bayle C. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol 1998; 103: 1212-1213.
15. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal zone lymphoma. Semin Hematol 1999; 36: 148-154.
16. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001; 91(2): 294-301.
17. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
18. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
19. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99: 158-161.
20. Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol 1998; 100: 609.
21. Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymph 2000; 40: 113-117.
22. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22-25.